Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.1K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.1K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

306
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
306
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

330
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
330
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

472
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
472
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonlinear Electrical Transport Unveils Fermi Surface Malleability in a Moiré Heterostructure.

Nano letters·2024
Same author

Navigating dermatological care: Experience with assisted teledermatology practice on e-Sanjeevani platform.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Light-Chain Deposition Diseases of the CNS: Review of Pathogenesis, Imaging Features, and Radiographic Mimics.

AJNR. American journal of neuroradiology·2024
Same author

Fear of Coronavirus Disease 2019 among People with Epilepsy.

The Journal of the Association of Physicians of India·2024
Same author

Managing outbreak of community-onset paediatric impetigo in underserved areas of North India via teledermatology: A tertiary care centre's experience.

Indian journal of dermatology, venereology and leprology·2024
Same author

Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates.

AJNR. American journal of neuroradiology·2024

Related Experiment Video

Updated: Mar 10, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

795

Practical Considerations in Managing Relapsed Multiple Myeloma.

Amit Agarwal1, Eric Chow2, Manisha Bhutani2

  • 1Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ.

Clinical Lymphoma, Myeloma & Leukemia
|December 18, 2016
PubMed
Summary
This summary is machine-generated.

Novel agents and combinations improve outcomes for relapsed/refractory multiple myeloma. This review discusses new treatment paradigms, stem cell transplantation, and personalized strategies for managing this complex blood cancer.

Keywords:
CarfilzomibDaratumumabElotuzumabPomalidomideRefractoryTransplantTreatment

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Related Experiment Videos

Last Updated: Mar 10, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

795
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma treatment has advanced significantly with new drug approvals.
  • Phase III data support incorporating a third novel agent into existing platforms.

Purpose of the Study:

  • To review novel treatment paradigms for relapsed/refractory multiple myeloma.
  • To discuss the role of stem cell transplantation in current treatment strategies.
  • To propose personalized treatment approaches based on disease and patient factors.

Main Methods:

  • Review of phase III clinical trial data.
  • Analysis of regulatory approvals for novel agents.
  • Discussion of autologous and allogeneic stem cell transplantation outcomes.

Main Results:

  • Combination therapies demonstrate improved response rates and durability.
  • Novel agents show promising activity in relapsed/refractory multiple myeloma.
  • Toxicity profiles are generally acceptable with novel combinations.

Conclusions:

  • Novel agents and combinations represent a significant advance in multiple myeloma therapy.
  • Stem cell transplantation remains a key consideration in treatment sequencing.
  • Personalized strategies are essential for optimizing outcomes in relapsed/refractory disease.